您現在的位置: > Language Tips > Audio & Video > Special Speed News  
     





      Once-daily pill could simplify HIV treatment
    [ 2006-02-06 15:57 ]


    I’m Steve Ember with the VOA Special English Health Report.


    Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
    Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

    But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

    Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

    They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

    Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

    In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

    Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

    GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

    The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

    They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

    There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

    Experts say more than forty million people around the world are living with H.I.V.

    This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

    Vocabulary

     

     

     
     
     




    一本一道av中文字幕无码| 亚洲精品无码专区久久久| 亚洲AV无码成人精品区蜜桃| 中文有无人妻vs无码人妻激烈| 无码精品A∨在线观看中文| 最近中文字幕免费2019| 无码专区国产无套粉嫩白浆内射| 无码日韩精品一区二区三区免费 | 暴力强奷在线播放无码| 色综合久久综合中文综合网| av无码一区二区三区| 亚洲AV无码专区国产乱码电影 | 最近最新高清免费中文字幕| 亚洲AV无码专区日韩| 狠狠噜天天噜日日噜无码| 亚洲性无码一区二区三区| 久久精品99无色码中文字幕| 国偷自产短视频中文版| 国产日韩精品无码区免费专区国产| 中文字幕无码AV波多野吉衣| 中文字幕av日韩精品一区二区| 中文字幕乱妇无码AV在线| 亚洲中文字幕无码爆乳av中文| 超清纯白嫩大学生无码网站| 青青草无码免费一二三区| 亚洲大尺度无码无码专区| 亚洲V无码一区二区三区四区观看 亚洲爆乳精品无码一区二区三区 亚洲爆乳无码一区二区三区 | 亚洲 另类 无码 在线| 特级小箩利无码毛片| 精品久久久久久无码国产| 国产精品无码午夜福利| 日日麻批免费40分钟无码| 无码AV岛国片在线播放| 无码aⅴ精品一区二区三区浪潮| 无码人妻一区二区三区在线视频| 亚洲AV无码一区二区乱孑伦AS | 无码区国产区在线播放| 日韩乱码人妻无码中文字幕| 精品欧洲AV无码一区二区男男| 国产AV无码专区亚洲AV男同 | 丝袜熟女国偷自产中文字幕亚洲|